Biocon, Zentiva get nod for Liraglutide in European Union

24 Dec 2024 Evaluate

Biocon and its European partner, Zentiva, have received a Decentralized Procedure (DCP) approval for its complex formulation, Liraglutide, in the European Union (EU). The approval is for the generic versions of Victoza to treat Type-2 Diabetes and Saxenda used in the treatment of weight management.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

380.15 2.35 (0.62%)
16-Feb-2026 13:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.25
Dr. Reddys Lab 1269.00
Cipla 1350.00
Zydus Lifesciences 906.85
Lupin 2220.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×